Tag Archive for: Diagnostics

New paper in Frontiers in Medicine reveals first reliable biomarker test for early kidney transplant rejection detection in living-donor recipients

/in

Use of numares’ metabolite constellation showed a stable urinary metabolic profile in the first 14 days for living donor recipients, enabling accurate early rejection detection Deceased donor recipients exhibit ischemia‑driven metabolic alterations that transiently mask rejection signals Groundbreaking study was led by researchers at University Hospital Regensburg in conjunction with numares Health Regensburg, Germany, 09 […]

Read more

numares Health enters ASEAN region with regulatory approval in Malaysia and first contract win for AXINON ® LDLp Test System

/in

AXINON® LDLp Test System receives Medical Device Authority (MDA) in Malaysia numares Health appoints BioD Medica for local distribution MDA filing for additional CE-marked product is currently in progress   Regensburg, Germany, 16 December 2025 – numares Health (“numares”), the transformative metabolomics company pioneering multidimensional biomarker insights that deliver clinical pathways for optimal patient care, […]

Read more

Researchers aim to advance quantum sensing to transform disease diagnosis and prevention

/in

With its unprecedented precision, quantum sensing holds the potential to reform biomedical and health sciences by improving the diagnosis and prevention of diseases. The Novo Nordisk Foundation has awarded a grant of DKK 150 million to establish the Copenhagen Center for Biomedical Quantum Sensing, under which an international research collaboration aims to develop novel quantum sensing […]

Read more

ImaginAb Announces First Patient Dosed in Australia in Phase IIb iPREDICT Trial

/in

Los Angeles, California, USA, October 25th, 2022 – ImaginAb Inc., a global biotechnology company developing 89Zr crefmirlimab berdoxam (CD8 ImmunoPET) imaging agent and next generation radiopharmaceutical therapies (RPT) products, is pleased to announce that the first patient has been dosed at the Macquarie University Hospital in Sydney, Australia as part of its Phase IIb iPREDICT […]

Read more
© Optimum Strategic Communications.